Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia
- 20 December 2003
- journal article
- research article
- Published by Elsevier in Human Pathology
- Vol. 34 (12), 1313-1320
- https://doi.org/10.1016/s0046-8177(03)00406-4
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Mechanisms and consequences of somatic mosaicism in humansNature Reviews Genetics, 2002
- Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patientsHuman Mutation, 2002
- In Vivo Selection of Hepatocytes Transduced with Adeno-Associated Viral VectorsMolecular Therapy, 2000
- Adenovirus-Mediated Gene Therapy in a Mouse Model of Hereditary Tyrosinemia Type IHuman Gene Therapy, 1997
- The Mutagenicity of the Tyrosine Metabolite, Fumarylacetoacetate, Is Enhanced by Glutathione DepletionBiochemical and Biophysical Research Communications, 1997
- Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type INature Genetics, 1996
- Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type INature Genetics, 1995
- Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.Journal of Clinical Investigation, 1993
- Incidence and Diagnostic Features of Macroregenerative Nodules Vs. Small Hepatocellular Carcinoma in Cirrhotic LiversHepatology, 1992
- Neurologic Crises in Hereditary TyrosinemiaNew England Journal of Medicine, 1990